MYELODYSPLASTIC SYNDROMES

This study tests a new drug called elritercept (KER-050) in 160 adults with a bone marrow condition called myelodysplastic syndromes (MDS) who have low red blood cells (anemia). The main goal is to check the drug's safety and find the best dose. Researchers will also see if it he…

This study tests whether adding interferon-γ to donor white blood cell infusions can help control acute myeloid leukemia or myelodysplastic syndromes that have returned after a stem cell transplant. About 45 adults will receive the combination and be monitored for at least a year…

This study looks at whether getting a stem cell transplant right away is as good as getting some treatment first and then the transplant for people with higher-risk myelodysplastic syndrome (MDS). About 236 adults who are eligible for a transplant will be randomly assigned to one…

This study is for people with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) who have received a stem cell transplant from a half-matched donor. After the transplant, patients will get extra immune cells called natural killer (NK) cells from the same donor to hel…

This study tests a stem cell transplant method for people with blood cancers like leukemia. It uses lower-dose chemotherapy before the transplant and special drugs afterward to help prevent the donor cells from attacking the patient's body. The goal is to improve survival and red…

This study tests a treatment for people with myelodysplastic syndromes (a type of blood cancer) who are at intermediate or high risk and cannot have a standard stem cell transplant. Participants will receive a drug called venetoclax plus another drug, along with an infusion of im…

This study tests if luspatercept is better than epoetin alfa at preventing the need for blood transfusions in adults with a certain type of low-risk myelodysplastic syndrome (MDS) who have anemia but haven't needed transfusions yet. About 360 participants will receive one of the …

This study tests whether specially trained natural killer (NK) cells can help prevent acute myeloid leukemia, myelodysplastic syndrome, or related blood cancers from coming back after a stem cell transplant. About 15 adults at high risk of relapse will receive an infusion of thes…

This study tests a combination of four drugs (cladribine, cytarabine, venetoclax, and azacitidine) to see if it can help control higher-risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) that has not responded to standard treatments. About 60 adults age…

This early-phase trial tests a new cell therapy called Orca-T in people with advanced blood cancers (like leukemia) who are getting a stem cell transplant from a partially matched donor. The goal is to see if Orca-T can reduce serious complications, such as graft-versus-host dise…

This early-stage trial tests whether adding decitabine and venetoclax to a standard stem cell transplant is safe for people with high-risk blood cancers like leukemia. About 20 adults aged 18-75 with a matching donor will take part. The goal is to find the best dose that limits s…

This study tests a drug called pacritinib in people aged 12 and older with myelodysplastic syndromes (MDS) or related blood disorders. The drug is taken as a capsule twice daily and aims to control the disease by blocking certain proteins that help cancer grow. Researchers will f…

This study tests whether adding venetoclax to the standard chemotherapy given before a stem cell transplant can help prevent relapse in people with high-risk acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). About 138 patients aged 12 to 60 will be randomly assigne…

This study tests whether adding the drug momelotinib to standard treatment can better control rare blood cancers like chronic myelomonocytic leukemia and chronic neutrophilic leukemia. About 18 adults will take momelotinib pills plus a standard injection for up to 24 months. The …

This study tests if using two different stem cell donors together can help people with certain blood cancers (like leukemia) live longer without the cancer coming back. About 36 adults will receive a transplant from a half-matched family donor plus a cord blood donor. The main go…

This early-stage study tests a new drug called SX-682, alone or with another drug (decitabine), in people with myelodysplastic syndrome (MDS), a type of blood cancer. The main goal is to find the safest dose and understand side effects. About 151 adults whose MDS has not responde…

This early-phase study tests whether adding an experimental drug (defactinib) to an approved oral treatment (decitabine/cedazuridine) is safe and can work better for people with certain blood cancers like MDS, AML, and CMML. About 12 adults will take the approved drug alone for t…

This study tests a new, lower-dose weekly schedule of two approved drugs (decitabine and venetoclax) for people with bone marrow cancers like MDS, AML, and CMML. The goal is to see if this gentler approach can control the disease while causing fewer treatment delays or interrupti…

This early-phase trial tests a new approach for people with advanced blood cancers who are getting a stem cell transplant. Instead of using strong drugs to prevent graft-versus-host disease (a common complication where donor cells attack the patient), researchers will give specia…

This study tests an oral drug (ASTX030) that combines two medicines to treat certain blood cancers like myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML). The goal is to see if taking a pill works as well as getting a shot. …

This program offers galinpepimut-S, an experimental immune therapy, to individual patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who have run out of standard treatments. It is for those who cannot join a clinical trial and have no other suitable opti…

This early-phase study tests a drug called venetoclax combined with standard chemotherapy for adults newly diagnosed with acute myeloid leukemia (AML) or advanced myelodysplastic syndrome (MDS). The goal is to find the safest dose and see how well the combination works. About 99 …

This study tests whether momelotinib can safely help people with low-risk myelodysplastic syndromes (MDS) who have anemia. About 80 adults will receive different doses to find the best one that reduces or eliminates the need for red blood cell transfusions. The goal is to improve…

This early-phase study tests a new treatment for adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who still have small amounts of cancer cells after standard therapy. The treatment uses the patient's own blood cells that are specially prepared in the lab…

This early-phase study tests a new type of donor cell graft called Orca-Q in 300 people with blood cancers like leukemia or myelodysplastic syndromes who need a stem cell transplant. The graft is engineered from a donor's blood cells to try to reduce complications like graft-vers…

This early-phase trial tests a new treatment for people whose leukemia or related blood cancers return after a stem cell transplant. The therapy uses specially trained natural killer (NK) cells from a donor, followed by low-dose IL-2 to help them work. The main goal is to find th…

This study tests an experimental drug called enzomenib in about 600 people with acute leukemia and certain other blood cancers. The goal is to find the safest dose and see if the drug can shrink or control the cancer. Participants must have cancers that came back or did not respo…

This study is testing an experimental drug called BGB-11417 for people with acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), or related blood cancers. The drug blocks a protein that helps cancer cells survive. The trial will find the best dose and see if the drug wo…

This early-phase study tests a new oral drug called BH-30236 in adults whose acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) has returned or not responded to prior treatments. The main goals are to check safety, find the right dose, and see if the drug ca…

This study tests whether giving a drug combination (decitabine and cedazuridine, or DEC-C) early can prevent myelodysplastic syndromes (MDS) from coming back after a stem cell transplant. About 209 adults who have had a transplant and still have tiny amounts of cancer cells (meas…

This study tests whether tranexamic acid (TXA), a medication that helps blood clots stay in place, can safely reduce bleeding in people with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML). About 75 adults receiving low-intensity chemotherapy and having low platel…

This study is testing whether giving blood transfusions at home is practical and okay for cancer patients who need transfusions often. About 30 adults with blood cancers or bone marrow problems will receive 1-5 units of blood products at home. Researchers will track how often tra…

This study collects blood, bone marrow, and other samples from people with non-cancerous blood diseases and their family members. Researchers will analyze the genetic information to find new genes linked to these conditions and understand why some people get sicker than others. T…

This study looks at whether certain proteins in the blood (called cytokines) can help predict how well older or sicker patients with acute myeloid leukemia, high-risk myelodysplastic syndrome, or chronic myelomonocytic leukemia will do on a gentler type of chemotherapy. Researche…

This study is testing whether a new whole genome test called ChromoSeq can find genetic changes in people with myelodysplastic syndrome (MDS) as well as current standard tests. About 60 adults with suspected or confirmed MDS will provide samples, and doctors will compare the resu…

This study is gathering health information from 2,000 people who are getting a stem cell transplant for blood cancers or immune disorders. The goal is to track survival and complications to help improve future treatments and hospital operations. No experimental drugs or procedure…

This study aims to find genetic changes that cause early blood conditions to turn into cancer. Researchers will collect blood, bone marrow, or cheek swab samples from up to 10,000 people who have or are at risk for certain blood cancers. The goal is to better understand how these…

This study follows people with a gene change (DDX41) that raises the risk of blood cancers like MDS and AML, along with their relatives. Researchers will collect health information, blood, and other samples over 10 years to learn how these inherited risks lead to cancer. No treat…

This study follows up to 1,100 people with myelodysplastic syndromes (MDS) and healthy donors for up to 20 years. Researchers collect blood, bone marrow, and other samples to learn how the disease progresses and to find better treatments. No experimental therapy is given; the goa…

This study is testing whether an artificial intelligence (AI) tool can help connect cancer patients with the right clinical trials. Researchers will enroll up to 50,000 people with various cancers and use the AI to suggest trials based on their tumor's genetic markers. The goal i…